BRIEF-Biorestorative Therapies To Seek FDA Approval To Expand The Clinical Application Of BRTX-100
Reuters · 03/13 11:47
BioRestorative engages advisory firm for clinical application of cell therapy BRTX-100
Seeking Alpha · 03/13 11:23
BioRestorative Therapies Hires Advisory Firm to Expand Drug Candidate Indication Pipeline
BioRestorative Therapies Hires Advisory Firm to Expand Drug Candidate Indication Pipeline
MT Newswires · 03/13 11:22
EXCLUSIVE: BioRestorative Seeks Expanded FDA Approval For BRTX-100 Clinical Application, Engages Advisory Firm
Benzinga · 03/13 10:30
Pre-market Movers: CARA, SFR, WW, SQSP, SLND…
NASDAQ · 03/07 12:41
12 Health Care Stocks Moving In Monday's After-Market Session
Benzinga · 03/06 21:31
Maxim Group Keeps Their Buy Rating on BioRestorative Therapies (BRTX)
TipRanks · 03/03 17:15
Marvell Technology, Zscaler, Bumble among premarket losers' pack
Seeking Alpha · 03/03 13:37
BTRX Blasts Up with New Patent
TipRanks · 03/02 20:26
Why BioRestorative Therapies Stock Is Climbing Higher Today
Benzinga · 03/02 19:39
Dow Jumps Over 300 Points; Best Buy Profit Beats Views
Benzinga · 03/02 19:31
Why Cano Health Shares Are Trading Lower By Around 23%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Benzinga · 03/02 18:32
12 Health Care Stocks Moving In Thursday's Intraday Session
Benzinga · 03/02 17:31
Dow Rises 100 Points; Macy's Posts Upbeat Earnings
Benzinga · 03/02 17:24
Wall Street Mixed At Open; US Weekly Jobless Claims Decline
Benzinga · 03/02 15:05
OncoSec, BioRestorative top healthcare gainers; ZimVie, Cano among losers
Seeking Alpha · 03/02 15:00
BioRestorative surges ~30% on upcoming US patent linked to metabolic ThermoStem program
Seeking Alpha · 03/02 13:18
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Benzinga · 03/02 13:06
BRIEF-Biorestorative Therapies Receives Notice Of Allowance By The United States Patent And Trademark Office For A Patent Application Related To Its Thermostem® Program
Reuters · 03/02 12:56
EXCLUSIVE: BioRestorative To Receive Third US Patent For Metabolic ThermoStem Program
Benzinga · 03/02 12:00
Webull provides a variety of real-time BRTX stock news. You can receive the latest news about Biorestorative Therapies Inc through multiple platforms. This information may help you make smarter investment decisions.
About BRTX
BioRestorative Therapies, Inc. is a life sciences company, which is focused on the development of regenerative medicine products and therapies using cell and tissue protocols, primarily involving adult (non-embryonic) stem cells. It offers two developmental programs, namely Disc/Spine Program (brtxDisc) and Metabolic Program (ThermoStem), which relate to the treatment of disc/spinedisease and metabolic disorders. Its lead cell therapy candidate, BRTX-100, is a product formulated from autologous hypoxic cultured mesenchymal stem cell (MSC) product derived from a patient's own bone marrow and formulated with a biomaterial carrier (platelet lysate). BRTX-100 is used for the non-surgical treatment of painful lumbosacral disc disorders or as a complimentary therapeutic to a surgical procedure. It is engaged in developing a cell-based therapy candidate to target obesity and metabolic disorders using brown adipose (fat) derived stem cells (BADSC), to generate brown adipose tissue (BAT).